EP 0904102 A1 19990331 - MILK OF TRANSGENIC ANIMALS CONTAINING HUMAN ALPHA 1-ANTITRYPSIN AND USE OF HUMAN ALPHA 1-ANTITRYPSIN TO TREAT BILE ACID RELATED DISEASES
Title (en)
MILK OF TRANSGENIC ANIMALS CONTAINING HUMAN ALPHA 1-ANTITRYPSIN AND USE OF HUMAN ALPHA 1-ANTITRYPSIN TO TREAT BILE ACID RELATED DISEASES
Title (de)
HUMANES ALPHA-1S-ANTITRYPSIN IN DER MILCH TRANSGENER TIERE UND VERWENDUNG DESSELBEN ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT GALLENSÄURE
Title (fr)
LAIT D'ANIMAUX TRANSGENIQUE RENFERMANT UN- ALPHA 1-ANTITRYPSINE HUMAINE ET UTILISATION DE CETTE ALPHA 1-ANTITRYPSINE HUMAINE POUR LE TRAITEMENT DES MALADIES LIEES A L'ACIDE BILIAIRE
Publication
Application
Priority
- SE 9700465 W 19970320
- SE 9601091 A 19960321
Abstract (en)
[origin: WO9734628A1] The use of human alpha 1-antitrypsin as a foodstuff or as a medicament, utilizing its capacity to bind steroids and steroid-like substances, and transporting them in biological systems is described. Particularly the direct oral administration of the milk of transgenic animals containing abundant amounts (10-60 g/L) of human alpha 1-AT to reinstate a defect intestinal synthesis or to complement the normal physiological biosynthesis of alpha 1-AT is described. Such treatment will reduce the total body load of bile acids by increasing their gastrointestinal elimination. It is expected to be beneficial for bile acid related diseases such as all cholestatic liver diseases, and bile-reflux gastritis. Such treatment is expected to be particularly beneficial in cases of neonatal cholestasis, as newborns circulate large quantities of hydrophobic bile acids which cause liver injury and may contribute to injury of other tissues. It will be protective in cases where bile acids cause tissue injury such as vasculitis, glomerulonephritis, and inflammatory bowel disease. It will be beneficial against diarrhoea in intestinal bacterial overgrowth and bile acid malabsorption. Increased gastrointestinal elimination of the steroid structure may also reduce the total body load of cholesterol and thus be efficient in the treatment of hyperlipidemia.
IPC 1-7
IPC 8 full level
A61K 35/20 (2006.01); A61K 38/57 (2006.01); C07K 14/81 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP)
A61K 35/20 (2013.01); A61K 38/57 (2013.01); C07K 14/8125 (2013.01); A01K 2217/05 (2013.01)
Citation (search report)
See references of WO 9734628A1
Designated contracting state (EPC)
CH DE DK FR GB IT LI
DOCDB simple family (publication)
WO 9734628 A1 19970925; AU 2186497 A 19971010; EP 0904102 A1 19990331; SE 9601091 D0 19960321; SE 9601091 L 19970922
DOCDB simple family (application)
SE 9700465 W 19970320; AU 2186497 A 19970320; EP 97914726 A 19970320; SE 9601091 A 19960321